Instrument Inactif

Communiqués Tobira Therapeutics Inc Nasdaq

Actions

US75874Q1076

Recherche biotechnologique et médicale

Communiqués

20/10/16	Tobira Therapeutics : Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting	BU
03/10/16	Tobira Therapeutics : Announces Presentations Related to Cenicriviroc’s Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting	BU
21/09/16	TBRA Brower Piven Commences An Investigation Into The Proposed Sale Of Tobira Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	BU
21/09/16	Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of Tobira Therapeutics, Inc. to Allergan plc for $28.35 Per Share Is Fair to Shareholders	BU
20/09/16	TOBIRA PHARMACEUTICALS, INC. Rigrodsky & Long, P.A. Announces Investigation Of Buyout	BU
20/09/16	Tobira Therapeutics : Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH	PU
12/09/16	Tobira Therapeutics : Announces Initiation of Phase 1 Combination Study of Cenicriviroc and Evogliptin	BU
07/09/16	Tobira Therapeutics : Announces Appointment of Dr. Laurent Fischer as Industry Co-chair of the Liver Forum Steering Committee	BU
01/09/16	Tobira Therapeutics : to Participate in Two Conferences in September	BU
09/08/16	Tobira Therapeutics : Reports Second Quarter 2016 Financial and Business Results	BU
02/08/16	Tobira Therapeutics : to Present at the 36th Annual Canaccord Genuity Growth Conference	BU
01/08/16	Tobira Therapeutics Announces Date of 2016 Second Quarter Financial Results and CENTAUR Study Update Conference Call	GL
25/07/16	Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations of Federal Securities Laws by Certain Officers and Directors of Tobira Therapeutics, Inc.	BU
25/07/16	Tobira Therapeutics : Announces Clinically and Statistically Significant Improvement in Liver Fibrosis From Phase 2b CENTAUR NASH Trial at One Year	BU
25/07/16	Tobira Therapeutics to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss CENTAUR Phase 2b Trial Results	BU
27/06/16	Tobira Therapeutics : Cenicriviroc Reduces Inflammation and Fibrosis in Animal Models of Chronic Liver and Kidney Disease Including NASH	PU
27/06/16	Tobira Therapeutics : Cenicriviroc Reduces Inflammation and Fibrosis in Animal Models of Chronic Liver and Kidney Disease Including NASH	BU
16/06/16	Tobira Therapeutics : Cenicriviroc Shown to Reduce Liver Injury in Independent Research Published in the Journal Hepatology	PU
16/06/16	Tobira Therapeutics : Cenicriviroc Shown to Reduce Liver Injury in Independent Research Published in the Journal Hepatology	BU
02/05/16	Tobira Therapeutics Announces Date of 2016 First Quarter Financial Results and Conference Call	GL
22/02/16	Tobira Therapeutics Announces Date of 2015 Fourth Quarter Financial Results and Conference Call	GL
14/05/15	Tobira Therapeutics : to Present at the Bank of America Merrill Lynch 2015 Health Care Conference	PU
14/05/15	Tobira Therapeutics : Completes Financing and Merger with Regado Biosciences	PU
20/03/15	Tobira Therapeutics : Highlights Presentations at the AASLD’s Industry Colloquium for Novel Targets and Therapies in Liver Disease	PU
14/01/15	Tobira Therapeutics : Regado Biosciences and Tobira Therapeutics Announce Merger Agreement to Create Leading NASH Company	PU